Cited 0 times in Scipus Cited Count

A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial

DC Field Value Language
dc.contributor.authorKim, KH-
dc.contributor.authorLim, SM-
dc.contributor.authorAhn, HK-
dc.contributor.authorLee, YG-
dc.contributor.authorLee, KW-
dc.contributor.authorAhn, MJ-
dc.contributor.authorKeam, B-
dc.contributor.authorKim, HR-
dc.contributor.authorLee, HW-
dc.contributor.authorAn, HJ-
dc.contributor.authorKim, JS-
dc.date.accessioned2024-02-13T23:26:58Z-
dc.date.available2024-02-13T23:26:58Z-
dc.date.issued2024-
dc.identifier.issn1598-2998-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32173-
dc.description.abstractPURPOSE: Precision oncology approach for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is necessary due to its dismal prognosis. We performed a genomic profile-based umbrella trial of patients with platinum-refractory HNSCC (KCSG-TRIUMPH). Here, we present an in-depth report of the the nintedanib arm (arm 3) of the current trial. MATERIALS AND METHODS: The TRIUMPH study was a multicenter, open-label, single-arm phase 2 trial, in which patients were assigned to treatment arms based on next-generation sequencing (NGS)-based, matching genomic profiles. Patients whose tumors harbor fibroblast growth factor receptor (FGFR) alteration were enrolled in the nintedanib arm (arm 3) as part of the TRIUMPH study. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and biomarker analysis. RESULTS: Between October 2017 and August 2020, 207 were enrolled in the TRIUMPH study, and eight were enrolled in the nintedanib arm. ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months. One patient maintained the partial response for 36 months. Overall, the toxicity profiles were manageable. CONCLUSION: Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent or metastatic HNSCC patients, with tolerable toxicity profiles. The results from the study have provided the basis for routine NGS screening and FGFR-targeted therapy. Because of the small number of patients due to slow accrual in this study, further studies with a larger cohort are warranted for statistical power.-
dc.language.isoen-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHHead and Neck Neoplasms-
dc.subject.MESHHumans-
dc.subject.MESHIndoles-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHPrecision Medicine-
dc.subject.MESHSquamous Cell Carcinoma of Head and Neck-
dc.titleA Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial-
dc.typeArticle-
dc.identifier.pmid37475136-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789954-
dc.subject.keywordNGS-
dc.subject.keywordNintedanib-
dc.subject.keywordPrecision medicine-
dc.subject.keywordSquamous cell carcinoma of head and neck-
dc.subject.keywordUmbrella trial-
dc.contributor.affiliatedAuthorLee, HW-
dc.type.localJournal Papers-
dc.identifier.doi10.4143/crt.2023.433-
dc.citation.titleCancer research and treatment-
dc.citation.volume56-
dc.citation.number1-
dc.citation.date2024-
dc.citation.startPage37-
dc.citation.endPage47-
dc.identifier.bibliographicCitationCancer research and treatment, 56(1). : 37-47, 2024-
dc.identifier.eissn2005-9256-
dc.relation.journalidJ015982998-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
37475136.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse